Craft

Chugai Pharmaceutical

Stock Price

¥7.7 K

2024-10-29

Market Capitalization

¥12.1 T

2024-10-29

Revenue

¥1.3 T

FY, 2025

Chugai Pharmaceutical Summary

Company Summary

Overview
Chugai Pharmaceutical is a pharmaceutical company specializing in the fields of oncology, as well as bone, joint, and renal diseases. It offers Actemra, an agent for rheumatoid arthritis and other autoimmune diseases, and Alecensa, an inhibitor for non-small cell lung cancer. The company also provides GC33, an antibody for hepatocellular carcinoma, and other medicines.
Type
Public
Status
Active
Founded
1925
HQ
Chuo City, JP | view all locations
Website
https://www.chugai-pharm.co.jp/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

LocationsView all

10 locations detected

  • Chuo City, Tōkyō-to HQ

    Japan

    2-chōme-1-1 Nihonbashimuromachi

  • Berkeley Heights, NJ

    United States

    300 Connell Dr #3100

  • Guangzhou Shi, Guangdong Sheng

    China

    15 Zhujiang W Rd, Tianhe Qu

  • Taizhou

    China

    Hailing District

  • Shanghai Shi

    China

    381 Huaihai Road, Huai Hai Lu Dong Duan, Huangpu Qu

  • Puteaux, IDF

    France

    Tour Franklin

and 4 others

Chugai Pharmaceutical Financials

Summary Financials

Revenue (FY, 2025)
¥1.3T
Gross profit (FY, 2025)
¥903.5B
Net income (FY, 2025)
¥434.0B
Cash (Q1, 2026)
¥418.0B
EBIT (FY, 2025)
¥601.0B

Footer menu